Minimally invasive radiation treatment for wet AMD nears market


Howard Larkin
Published: Thursday, September 8, 2016
[caption id="attachment_5155" align="alignnone" width="750"]
Inserted into the sub-Tenon’s space, the lighted tip of the Salutaris SMD-DA can be seen through an ophthalmoscope, allowing precise positioning of a radioisotope seed under wet AMD lesions
Salutaris Medical Devices introduced a new generation of its epsicleral brachytherapy device for treating necovascular age-related macular degeneration at the Ophthalmology Futures European Forum in Copenhagen, Denmark, Thursday. Designed to reduce the need for ongoing anti-VEGF intravitreal injections, the new device is expected to receive the CE Mark by year’s end, said Salutaris CEO Laurence J Marsteller MD.
“Our new commercial-ready applicator system is a significant marker of SalutarisMD’s continued progress and we are looking forward to positively affecting patient outcomes,” Dr Marsteller said.
The new SMD-DA device treats wet AMD by exposing a target lesion to a strontium-90 radioisotope seed delivering ionizing radiation with anti-angiogenic and anti-inflammatory effects. It consists of a curved cannula with a lighted tip, which is placed directly behind the target lesion. The seed is then advanced from the handle to precisely deliver a prescribed radiation dose. Because it does not penetrate the globe, the 15-minute outpatient procedure is safer than brachytherapy using an epimacular probe, which requires vitrectomy, Dr Marsteller noted.
SMD-DA improves dosimetry control over the first-generation SMD-1, increasing chances that the entire target lesion will be treated, Dr Marsteller said. In a test of the earlier device, three of four treatment-naïve patients and one of two chronically treated wet AMD patients saw best corrected visual acuity improve four to 25 letters two years following treatment. Two of the treatment-naïve patients required no further anti-VEGF injections at two years. The new device has received USA regulatory approval for an investigational clinical trial.

Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.